Research & Development: Page 30
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Genentech's Quita Highsmith
Quita Highsmith is changing how Genentech approaches diversity and inclusion across the board — from drug development to career advancement.
By Taren Grom • March 9, 2022 -
Stock via Getty Images
ProfileHorizon’s VP of R&D on her ascent in biotech — and bringing other female scientists along for the ride
Elizabeth Thompson is guiding Horizon through new drug approvals while leading the way for young women in STEM.
By Alexandra Pecci • March 8, 2022 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Stock via Getty Images
Two key factors behind NYC's record-setting rise in healthcare funding
According to a new report, women’s and digital health led to an explosion in funding last year in NYC.
By Robin Robinson • March 7, 2022 -
Stock via Getty Images
Are patients happy? This simple question could shake up clinical trials
The migration to DCTs is helping uncover critical gaps in patient experience.
By Kelly Bilodeau • March 4, 2022 -
Permission granted by Andrew Hopkins.
Q&AExscientia scored the largest AI deal with a Big Pharma to date — but it's just getting started
The company’s CEO on the road ahead for AI capabilities in pharma.
By Meagan Parrish • March 4, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Lyndra Therapeutics' CEO Dr. Trish Hurter
With Lyndra's ultra-long-acting therapies, Hurter and the company are aiming to reinvent medicines.
By Taren Grom • March 2, 2022 -
Diego Camargo/PharmaVoice
The 2022 PharmaVoice 100 — new look, same drive for excellence
Some of the industry’s biggest names have been on our list of honorees. Now it’s time to find this year’s inspiring leaders.
By Taren Grom • Feb. 28, 2022 -
Stock via Getty Images
Q&ACandel's CEO looks to help ignite a new era of cancer treatments
Candel Therapeutics is advancing a next-gen approach in oncology: using viruses to kill cancer cells at the site of injection.
By Taren Grom • Feb. 28, 2022 -
Stock via Getty Images
Q&AWhy plasma derived therapies have a unique edge in rare diseases
Takeda's head of PDT R&D explains how the Japanese drug giant is advancing these emerging treatments.
By Kim Ribbink • Feb. 25, 2022 -
Permission granted by Guadalupe Hayes-Mota
ProfileGuadalupe Hayes-Mota's 'recipe' for tackling pharma's supply chain issues
A quest to expand access to medical treatment globally led to a new career path when Guadalupe Hayes-Mota left his biotech leadership roles to start his own company.
By Robin Robinson • Feb. 25, 2022 -
Stock via Getty Images
Eisai's mission to shake off Aduhelm's shadow and bring another AD drug to market
The company's senior VP of clinical research on how they're building off the science of Aduhelm to develop better Alzheimer's treatments.
By Kelly Bilodeau • Feb. 23, 2022 -
Stock via Getty Images
QSAM's rare cancer treatment could be a game-changer
For patients with osteosarcoma, amputation can be the only option — but QSAM's CEO hopes to change that.
By Alexandra Pecci • Feb. 17, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Organon's Chief Commercial Officer Susanne Fiedler
Susi Fiedler, chief commercial officer, was instrumental in the spinout of Organon as a standalone company focused on a broad range of women’s health issues.
By Taren Grom • Feb. 16, 2022 -
Stock via Getty Images
ProfileHow Veru is developing blockbuster drugs while avoiding biotech's 'valley of death'
Why sexual health and telemedicine are key to the company's goals in oncology.
By Meagan Parrish • Feb. 16, 2022 -
Stock via Getty Images
How a 'powerful form' of data capture is transforming pharma labs
AnIML, an open data format, is helping the industry build labs of the future.
By Robin Robinson • Feb. 15, 2022 -
Stock via Getty Images
OpinionIndustry executives on the milestone moments shaping pharma's future
Scientific, technological, and communication changes that are making a permanent impact on the industry.
By Taren Grom • Feb. 9, 2022 -
Permission granted by Mike Rea.
Q&AInnovation vs. invention
IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.
By Taren Grom • Feb. 9, 2022 -
Courtesy of Saniona
Q&ASaniona's CEO on why it takes a village to develop treatments for a rare disease
Saniona built its village by first hiring a head of patient advocacy.
By Kim Ribbink • Feb. 8, 2022 -
Retrieved from Google image.
Q&AGaining real-world results from a decentralized trial
Lark’s principal Investigator OraLee Branch hopes a DCT will lead the company to their true audience.
By Kelly Bilodeau • Feb. 8, 2022 -
Courtesy of 23andMe
Q&AWhy 23andMe's first solo clinical trial is a big deal
It's the first test for a compound developed with the help of the company's genetic data — and there could be plenty more to come.
By Taren Grom • Feb. 7, 2022 -
Retrieved from MaxPixel.
Pharma's pain points with AI
Looking beyond the buzz and at the challenges associated with AI.
By Meagan Parrish • Feb. 7, 2022 -
Permission granted by Datacubed Health
Sponsored by Datacubed HealthSafety Monitoring: What does ePRO have to do with it?
Safety monitoring is critical to clinical trials. Learn how ePRO can play a role. Read the article.
Feb. 7, 2022 -
Courtesy of Web Sun
Komodo Health's partnership with Chan Zuckerberg Initiative gives 50 rare disease patient organizations access to next-generation analytics
With 330 million patient healthcare encounters in its database, Komodo assists advocacy organizations in gaining insights on specific patient populations.
By Robin Robinson • Feb. 3, 2022 -
Permission granted by Mary Harmon
Q&APTC's vice president of patient relations outlines the importance of patient input in rare disease R&D
You can't know what matters to rare disease patients unless you ask them.
By Kim Ribbink • Feb. 3, 2022 -
Permission granted by Peter Anastasiou
Q&A // First 90 DaysNew Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality
Read what Capsida CEO Peter Anastasiou has planned for his new role.
By Taren Grom • Feb. 3, 2022
Previous
